Top Page
Tvardi Therapeutics
(NASDAQ:TVRD)
Tvardi Therapeutics (TVRD) vs. SPDR S&P 500 ETF (SPY)
Tvardi Therapeutics Business Overview & Revenue Model
Tvardi Therapeutics Earnings Call Summary
Tvardi Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.58M | 7.14M | 20.97M | 41.87M | 23.03M | 135.08M |
| Gross Profit | 6.42M | 6.33M | 14.54M | 34.35M | 21.47M | 0.00 |
| EBITDA | -26.76M | -62.60M | -17.25M | -20.45M | -86.89M | 8.73M |
| Net Income | -20.89M | -70.87M | -17.35M | -20.54M | -88.44M | 8.41M |
Balance Sheet | ||||||
| Total Assets | 43.75M | 43.83M | 27.00M | 45.10M | 247.06M | 271.16M |
| Cash, Cash Equivalents and Short-Term Investments | 40.99M | 37.90M | 22.92M | 43.74M | 167.03M | 180.93M |
| Total Debt | 254.00K | 44.45M | 368.00K | 450.00K | 3.67M | 5.28M |
| Total Liabilities | 10.82M | 48.42M | 89.06M | 90.15M | 19.53M | 22.16M |
| Stockholders Equity | 32.93M | -4.59M | -62.06M | -45.05M | 227.52M | 249.00M |
Cash Flow | ||||||
| Free Cash Flow | -31.58M | -61.96M | -21.04M | -17.92M | -60.13M | -5.84M |
| Operating Cash Flow | -31.58M | -60.92M | -21.04M | -17.87M | -60.09M | -5.49M |
| Investing Cash Flow | -12.93M | 48.74M | 22.47M | -22.00M | -4.75M | -20.27M |
| Financing Cash Flow | 20.71M | -3.60M | 2.00K | 4.00K | 46.61M | 39.14M |
Tvardi Therapeutics Technical Analysis
Tvardi Therapeutics Risk Analysis
Tvardi Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
41 Neutral | $55.42M | -1.31 | -195.55% | ― | -0.11% | 43.47% | |
41 Neutral | $69.99M | ― | ― | ― | -8.16% | 22.44% | |
38 Underperform | $44.35M | -0.36 | -87.74% | ― | -60.16% | ― | |
37 Underperform | $41.17M | -0.25 | -93.85% | ― | -40.16% | 78.28% |
Tvardi Therapeutics Corporate Events
Tvardi Therapeutics Inc. is conducting a study titled REVERT- Liver Cancer: A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma. The study aims to assess the safety, tolerability, and preliminary efficacy of TTI-101, both as a standalone treatment and in combination with other therapies, for patients with advanced liver cancer.
On October 13, 2025, Tvardi Therapeutics provided an update on preliminary data from its Phase 2 REVERT trial for idiopathic pulmonary fibrosis (IPF), revealing that the study did not meet its goals. Despite the trial’s randomized, double-blind, placebo-controlled design, no significant differences in lung function improvement were observed between the treatment and placebo groups, with high discontinuation rates due to gastrointestinal adverse events. Tvardi plans further analysis to understand these results and continues to develop its next-generation STAT3 inhibitor, TTI-109, with preliminary data expected in 2026.
The most recent analyst rating on (TVRD) stock is a Hold with a $61.00 price target. To see the full list of analyst forecasts on Tvardi Therapeutics stock, see the TVRD Stock Forecast page.
Tvardi Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 for the treatment of fibrosis-driven diseases. In its latest earnings report for the quarter ending June 30, 2025, Tvardi Therapeutics highlighted a significant merger with Cara Therapeutics, resulting in a substantial increase in its cash position and a strategic shift in its corporate structure. The company’s financial performance showed a net income of $4.2 million for the quarter, a notable improvement from a net loss of $7 million in the same period last year, primarily driven by a gain from the fair value remeasurement of convertible notes. Despite the positive quarterly results, Tvardi reported a net loss of $5.4 million for the first half of 2025, reflecting ongoing investments in research and development. The company continues to face challenges typical of early-stage biopharmaceutical firms, including the need for additional financing to support its operations and research activities. Looking ahead, Tvardi remains focused on advancing its lead product candidate, TTI-101, through clinical trials, while seeking strategic partnerships and additional funding to ensure its long-term viability.
Tvardi Therapeutics Inc. faces a potential business risk due to its amended and restated certificate of incorporation, which mandates that the Court of Chancery of the State of Delaware is the exclusive forum for most disputes between the company and its stockholders. This provision could limit stockholders’ ability to seek a favorable judicial forum and increase the cost of bringing claims against Tvardi, potentially discouraging lawsuits. However, if a court finds this provision unenforceable, Tvardi may incur significant additional costs litigating in other jurisdictions, which could adversely affect its business operations and financial condition. The uncertainty surrounding the enforceability of these exclusive forum provisions poses a risk to Tvardi’s legal strategy and financial stability.